David Chiswell, PhD
Chief Executive Officer
Dr Chiswell has over 30 years' experience in the biotechnology industry having co-founded Cambridge Antibody Technology (CAT) in 1990, serving as CEO from 1996 to 2002. CAT listed on the London Stock exchange in April 1997 and Nasdaq in June 2001, and was subsequently sold to AstraZenca where it forms an important part of their biopharmaceutical franchise.
Since leaving CAT in 2002, he has focused on the development of early-stage biotechnology companies, having previously served as a director of Arakis, non-executive chairman of Sosei, Arrow Therapeutics and Daniolabs, and as CEO of Nabriva Therapeutics (2009 to 2012). Dr Chiswell currently serves as chairman of Albireo Pharma and is a director of Nabriva Therapeutics. He is a past chairman of the UK BioIndustry association (BIA) and in 2006 he was awarded the Most Excellent Order of the British Empire (OBE) by Her Majesty the Queen for services to the biotechnology industry.
Allan Bradley, PhD, FRS
Chief Technical Officer
Professor Bradley completed his PhD studies in genetics at the University of Cambridge in 1984. Working with Liz Robertson in the laboratory of Martin Evans, who shared the Nobel Prize for Physiology or Medicine in 2007, they showed that embryonic stem cells could be used to stably modify mouse genes.
In 1987 Professor Bradley moved to Baylor College of Medicine, Houston, Texas, where his laboratory developed novel methods to engineer the genomes of mice. He was appointed Investigator with the Howard Hughes Medical Institute in 1993 and full Professor in 1994. In 2000, Dr Bradley returned to the UK as Director of the Welcome Trust Sanger Institute.
Professor Bradley is the author of almost 300 scientific articles and book chapters. He has been active in commercialising technology from his laboratory by founding several companies including a publicly traded genomics company, Lexicon Genetics Inc.
In July 2002 he was elected Fellow of the Royal Society. In 2010 he was appointed Emeritus Director of the Sanger Institute, to support the development of Kymab, the first spin-out company launched by the Sanger institute.
Steve Arkinstall, DPhil
Chief Scientific Officer
Dr Arkinstall brings over 25 years of experience in biopharmaceutical drug discovery research across a range of disease areas and technology platforms. Previously Dr Arkinstall worked at the prestigious Glaxo Institute for Molecular Biology in Switzerland where he studied receptor-linked signal transduction pathways as a basis for new drug target identification for several therapeutic indications.
Dr Arkinstall also worked for Serono in Boston USA, where he led the Serono Reproductive Biology Institute and also served as President of the Serono Research Institute with a focus on oncology drug discovery. Following its acquisition by Merck KGaA he also played several leadership roles within Merck Serono including Head of Global Novel Biological Entities and External Innovation. Dr Arkinstall obtained his DPhil (PhD) from the University of Oxford, UK.
Duncan Casson, PhD
Chief Development Officer
Dr Casson has over 25 years' experience in the development of biologics including antibodies, recombinant proteins and autologous therapies. He was previously Chief Operating Officer of PanGenetics, with responsibility for the development of its therapeutic antibody pipeline, leading to the licence of an anti-NGF antibody to Abbott Laboratories during a Phase I patient study.
Dr Casson was VP Programme Management and Manufacturing for Cambridge Antibody Technology, including responsibility for the project management and manufacturing development of six of CAT's antibodies. Prior to this he was pivotal in the development of novel biologics with Genzyme, including Seprafilm® and Carticel®, which have subsequently been successfully commercialised.
Chief Financial Officer
Ms Hyland has a strong track record within the biopharma sector, bringing with her over 25 years of financial experience with both public and private companies. Most recently, she served as Chief Financial Officer of BBI Diagnostics Group Ltd and FTSE-listed Vectura Group plc (LSE: VEC).
Ms Hyland currently serves as Non-executive Director and Chair of the Audit Committee of the FTSE-250 global specialty chemicals company, Elementis plc (LSE:ELM). Prior to Vectura, she held a number of senior finance position, including Director of Corporate Finance at the then FTSE 100 Celltech Group plc, Medeva plc and KPMG.
Ms Hyland is a Chartered Accountant (FCA), a Corporate Tax Adviser (CTA–AITI) and holds a degree in business studies from Trinity College, Dublin.
Nigel Clark, PhD
Senior Vice President, Business Development
Dr Clark has more than 15 years of commercial and managerial experience in the biotech and pharma industry. His strengths are in business and corporate development, licensing, M&A and in particular deal execution, having executed over 20 major transactions.
Dr Clark was formerly Chief Business Officer at Syntaxin, (successfully divested to Ipsen Pharma), Vice-President of business development at Vernalis and a member of the senior executive committee as well as President, Vernalis Canada. He has also held leadership roles at Ribotargets and British Biotech and was co-head of the Biotech business unit at Datamonitor.
Glenn A Friedrich, PhD
Chief Operating Officer
Dr Friedrich has led efforts to create new companies from early technological conception through business plans, equity financing and intellectual property strategies through to full operations. His strengths are in drug research and development, project management, operations, strategy and intellectual property protection.
His experience includes: Lexicon Genetics, Ceros Pharmaceuticals, Progression Therapeutics and Moleculin. Dr Friedrich also served as Venture Associate with BCM Technologies, the venture subsidiary of Baylor College of Medicine, Houston, Texas. Dr Friedrich worked on the founding of Kymab with Professor Bradley in 2009.
Jasper Clube, EPA CPA
Senior Vice President Intellectual Property and Chief Patent Counsel
Mr Clube is a European Patent Attorney and a Fellow of the Chartered Institute of Patent Attorneys. He has 25 years of experience in intellectual property, all of this time in the biotechnology and healthcare sectors.
He was previously Vice President of Intellectual Property at Domantis Limited (2001-2007), a company focused on the therapeutic application of human antibody single variable domains. In that role he built the patent strategy for the company from start-up to acquisition in 2007 by GlaxoSmithKline. This included successful litigation in the antibody space. Following the acquisition of Domantis, his work continued as Senior Patent Counsel responsible for patenting and licensing GSK antibody assets within its Biopharmaceuticals division. His previous experience also includes Patent Counsel at AstraZeneca.